Momenta Pharmaceuticals receives patent for enoxaparin

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that on September 7, 2010 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,790,466, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping". The patent includes claims to methods of analyzing and processing enoxaparin that involve identifying chain sequence information.

"This patent provides further validation of our innovative approach to the characterization and ongoing quality control of enoxaparin," said Craig Wheeler, President and CEO of Momenta. "Issuance of this patent strengthens our expanding portfolio of patents and pending applications related to methods and tools for the identification and analysis of enoxaparin, and provides intellectual property protection around enoxaparin sodium injection USP, also known as generic Lovenox®."